Ravagalimab
Based on 1 Customer Validation
Ravagalimab (ABBV-323) is a CD40 antagonist (EC50: 3.7 nM). Ravagalimab can be used for research of Crohn's disease.
연구목적의 판매만을 진행합니다. 환자를 대상으로 한 판매는 하지 않습니다.
- Purity : 99.31%
- CAS No.: 2050816-56-1
- 분자량:146.04 kDa
-
보관:Shipping with dry ice
Please store the product under the recommended conditions in the Certificate of Analysis.
Biological Activity
제품 설명
Isotype
Human IgG1 kappa
Recommend Isotype Controls
Species Reactivity
Human
IC50 & Target
[1]|
CD40 3.7 nM (EC50) |
In Vitro
Ravagalimab (0-100 nM, 2 days) inhibits CD86 upregulation on primary human B cells with an EC50 of 0.6 nM[2].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
Gene ID
Accession
Conjugated
Unconjugated
Reconsititution
The product can be reconstituted/diluted with sterile PBS or saline.
Format
-
Human IgG1 kappa
신청
ELISA, FACS, Functional assay
Verified Bioactivity
-
Flow Cytometry analysis of Raji cells labelling TNFRSF5/CD40 (red) with Ravagalimab (anti-TNFRSF5/CD40) (HY-P99821). Goat Anti-Human IgG (Alexa Fluor 488) (HY-P83776) at a dilution of 1/1000 was used as the secondary antibody. Blue-Human IgG1 kappa (HY-P99001). Black-Unlabelled control, cells without incubation with primary antibody.
Chemical Information
-
CAS No. 2050816-56-1
-
Appearance Liquid
-
분자량 146.04 kDa
-
Color Colorless to light yellow
-
SMILES
[Ravagalimab]
-
Synonyms
ABBV-323
-
선적
Shipping with dry ice.
-
Formulation
Please refer to the lot-specific COA for specific buffer information.
-
보관
Please store the product under the recommended conditions in the Certificate of Analysis.
순도&문서
-
Data Sheet (256 KB)
-
SDS (251 KB)
- English - EN (251 KB)
- Français - FR (251 KB)
- Deutsch - DE (251 KB)
- Norwegian - NO (251 KB)
- Español - ES (251 KB)
- Swedish - SV (251 KB)
- Italian - IT (251 KB)
- Korean - KR (251 KB)
- Portuguese - PT (251 KB)
-
Inhibitory Antibodies User Guide (603 KB)
References
[1]. Argiriadi MA, et al. CD40/anti-CD40 antibody complexes which illustrate agonist and antagonist structural switches. BMC Mol Cell Biol. 2019 Aug 5;20(1):29. [Content Brief]
[2]. Yu X, et al. Isotype Switching Converts Anti-CD40 Antagonism to Agonism to Elicit Potent Antitumor Activity. Cancer Cell. 2020 Jun 8;37(6):850-866.e7. [Content Brief]
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)